EUVIMEDEUVIMED entdecken
Übersichtsarbeit

HDL regulates the risk of cardiometabolic and inflammatory-related diseases: Focusing on cholesterol efflux capacity

Huiyuan Kang, Jingjin Song, Ye Cheng

International Immunopharmacology · 2024-09 · 138 · 112622

DOI: 10.1016/j.intimp.2024.112622 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Huiyuan Kang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Inflammation. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia, characterized by higher serum concentrations of low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglyceride (TG), and lower serum concentrations of high-density lipoprotein cholesterol (HDL-C), is confirmed as a hallmark of cardiovascular diseases (CVD), posing serious risks to the future health of humans. Aside from the role of HDL-C concentrations, the capacity of cholesterol efflux to HDL is being identified as an enssential messurement for the dyslipidemic morbidity. Through inducing the progression of reverse cholesterol transport (RCT), the HDL-related cholesterol efflux plays a vital role in atherosclerotic plaque formation. In addition, increasing results demonstrated that the relationships between cholesterol efflux and cardiovascular events might be influenced by multiple factors, such as atherosclerosis, diabetes, and, inflammatory diseases. These risk factors could affect the intracellular composition of HDL, which might subsqently influence the cholesterol efflux process induced by HDL particle. In the present comprehensive article, we summarize the latest findings which described the modulatory roles of HDL in cardiometabolic disorders and inflammatory related diseases, focusing on its capacity in mediating cholesterol efflux. Moreover, the potential mechanisms whereby HDL regulate the risk of cardiometabolic disorders or inflammatory related diseases, at least partly, via cholesterol efflux pathway, are also well-listed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesInflammationHumansAnimalsCholesterol, HDLCholesterolBiological TransportDyslipidemiasRisk FactorsLipoproteins, HDL

Stichwörter der Autor:innen

Cardiometabolic disorderCholesterol effluxHDL partilceInflammatory responseMacrophage

Substanzen

Cholesterol, HDLCholesterolLipoproteins, HDL

Autor:innen und Institutionen

  • Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China.
  • Department of Cardiology, the Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, Fujian, China. Electronic address: chengyeheart@163.com.

Zitieren

APA

Kang, H., Song, J., & Cheng, Y. (2024). HDL regulates the risk of cardiometabolic and inflammatory-related diseases: Focusing on cholesterol efflux capacity. International Immunopharmacology, 138, 112622. https://doi.org/10.1016/j.intimp.2024.112622

Vancouver

Kang H, Song J, Cheng Y. HDL regulates the risk of cardiometabolic and inflammatory-related diseases: Focusing on cholesterol efflux capacity. International Immunopharmacology. 2024;138:112622. doi:10.1016/j.intimp.2024.112622

BibTeX
@article{Kang2024,
  author = {Kang, Huiyuan and Song, Jingjin and Cheng, Ye},
  title = {HDL regulates the risk of cardiometabolic and inflammatory-related diseases: Focusing on cholesterol efflux capacity},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {138},
  pages = {112622},
  doi = {10.1016/j.intimp.2024.112622}
}
Kostenlos starten →